The Effects of an Oral PCSK9 Inhibitor on LDL Cholesterol Levels

The study enrolled 381 subjects with a risk for atherosclerotic cardiovascular disease in an LDL cholesterol level of between 70 and 160. Subjects were randomized between either receiving placebo or one of four escalating doses of the oral PCSK9 inhibitor that was under investigation. The treatment reduced the LDL cholesterol between 41.2% at the lowest dose and up to 60.9% at the highest dose, there was a similar adverse event rate across all treatment groups.